Department of Health and Social Care

While the Department does not hold data specifically on the number of Parkinson’s specialist staff in England, we do hold data on the number of doctors working in the wider specialities of neurology and geriatric medicine. As of August 2025, there were 2,010 full time equivalent (FTE) doctors working in the specialty of neurology and 6,284 in geriatric medicine in National Health Service trusts and other organisations in England. This includes 1,025 FTE consultant neurologists and 1,687 FTE consultant geriatricians.

These figures are based on NHS Digital’s workforce data and reflect staff employed by NHS trusts and other core NHS organisations in England. They do not include doctors working in private practice or outside NHS organisations.

The Department does not hold specific data on the number of specialist Parkinson’s nurses currently working in the NHS in England. These roles are commissioned and managed locally by NHS trusts and integrated care boards as part of neurology and movement disorder services.

NHS England has published a service specification for specialised adult neurology services, which includes Parkinson’s disease as part of its scope. This specification sets out requirements for multidisciplinary care, including access to Parkinson’s disease nurse specialists, consultant neurologists, and allied health professionals.

NHS England is also implementing initiatives such as the Neurology Transformation Programme and the Getting It Right First Time Programme for Neurology, which aim to improve access to specialist care, reduce variation, and develop integrated models of service delivery for conditions including Parkinson’s disease. These programmes align with the National Institute for Care Excellence guidance on Parkinson’s disease, reference code NG71, which recommends that people with Parkinson’s have regular access to specialist staff with expertise in the condition.

While the Department does not hold data specifically on the number of Parkinson’s specialist staff in England, we do hold data on the number of doctors working in the wider specialities of neurology and geriatric medicine. As of August 2025, there were 2,010 full time equivalent (FTE) doctors working in the specialty of neurology and 6,284 in geriatric medicine in National Health Service trusts and other organisations in England. This includes 1,025 FTE consultant neurologists and 1,687 FTE consultant geriatricians.

These figures are based on NHS Digital’s workforce data and reflect staff employed by NHS trusts and other core NHS organisations in England. They do not include doctors working in private practice or outside NHS organisations.

The Department does not hold specific data on the number of specialist Parkinson’s nurses currently working in the NHS in England. These roles are commissioned and managed locally by NHS trusts and integrated care boards as part of neurology and movement disorder services.

NHS England has published a service specification for specialised adult neurology services, which includes Parkinson’s disease as part of its scope. This specification sets out requirements for multidisciplinary care, including access to Parkinson’s disease nurse specialists, consultant neurologists, and allied health professionals.

NHS England is also implementing initiatives such as the Neurology Transformation Programme and the Getting It Right First Time Programme for Neurology, which aim to improve access to specialist care, reduce variation, and develop integrated models of service delivery for conditions including Parkinson’s disease. These programmes align with the National Institute for Care Excellence guidance on Parkinson’s disease, reference code NG71, which recommends that people with Parkinson’s have regular access to specialist staff with expertise in the condition.

The new HIV Action Plan (HIV AP), published on 1 December 2025, sets out how the Government will enable every level of the healthcare system to work together to engage everyone in prevention, testing and treatment, tackling stigma, and reaching our ambition to end new HIV transmissions by 2030.

National Health Service integrated care boards hold commissioning responsibility for adult HIV services in line with the relevant NHS England service specification. NHS England is supportive of the HIV AP and its recommendations and is committed to the implementation and delivery of the plan.

The HIV AP asks local partners across the NHS and local authorities to carry out a HIV needs assessment which will inform the development and publication of local HIV plans across the country during 2026/27.

Local areas will monitor uptake and outcomes to identify gaps and improve equity in access to HIV prevention, testing, and treatment. The UK Health Security Agency will continue to support this with robust data monitoring and reporting.

As part of the new HIV Action Plan, we will continue the success of the blood-borne virus emergency department opt-out testing programme, investing £156 million from April 2026 to March 2029 to deliver opt-out HIV, Hepatitis B, and Hepatitis C testing in emergency departments in very high and high HIV prevalence areas.

We will also expand digital provision of HIV testing, investing £5 million in 2025/26 to trial HIV testing through the NHS App, working in partnership with existing commissioned sexual health providers, such as those already used by local authorities, rather than building a new service from scratch. These services have a strong track record in at-home HIV testing, and the NHS App will provide a new entry point that routes people into that established service.

National Health Service trusts are responsible for ensuring laboratories have adequate capacity for all testing, including HIV screening.

Improving cancer outcomes, including for bladder cancer, is a priority for the Government. The forthcoming National Cancer Plan will set out further actions to improve earlier diagnosis, expand access to the latest treatments and technologies, and improve survival rates across England.

National cancer registry data shows a small but sustained decline in bladder cancer survival rates over recent years. One-year survival fell from approximately 72% to 69.6%, and five-year survival from 51.5% to 47.2% between 2007 to 2011 and 2016 to 2020.

To improve treatment times, we have invested £70 million of funding into new radiotherapy treatment machines to replace older, less efficient machines. These new machines are currently being rolled out to trusts throughout the country. These newer machines will reduce treatment times, boost productivity, and allow more patients to be seen over the same period.

In addition, non-specific symptom pathways have been introduced to speed up diagnosis for patients whose symptoms may indicate cancer but which do not align clearly with a specific tumour type. This helps ensure that more patients are referred, investigated, and diagnosed earlier, including cases of bladder cancer that present with broader or less specific symptoms.

The NHS Cancer Programme has commissioned 10 national clinical audits covering breast, ovarian, pancreatic, lung, prostate, oesophago-gastric, bowel, non-Hodgkin lymphoma, and kidney cancers. These were selected as auditing was expected to have the greatest impact on reducing unwarranted variation in care. For this reason, there are currently no plans to undertake a national clinical audit for bladder cancer, though bladder cancer outcomes continue to be monitored through existing national cancer datasets.

Improving cancer outcomes, including for bladder cancer, is a priority for the Government. The forthcoming National Cancer Plan will set out further actions to improve earlier diagnosis, expand access to the latest treatments and technologies, and improve survival rates across England.

National cancer registry data shows a small but sustained decline in bladder cancer survival rates over recent years. One-year survival fell from approximately 72% to 69.6%, and five-year survival from 51.5% to 47.2% between 2007 to 2011 and 2016 to 2020.

To improve treatment times, we have invested £70 million of funding into new radiotherapy treatment machines to replace older, less efficient machines. These new machines are currently being rolled out to trusts throughout the country. These newer machines will reduce treatment times, boost productivity, and allow more patients to be seen over the same period.

In addition, non-specific symptom pathways have been introduced to speed up diagnosis for patients whose symptoms may indicate cancer but which do not align clearly with a specific tumour type. This helps ensure that more patients are referred, investigated, and diagnosed earlier, including cases of bladder cancer that present with broader or less specific symptoms.

The NHS Cancer Programme has commissioned 10 national clinical audits covering breast, ovarian, pancreatic, lung, prostate, oesophago-gastric, bowel, non-Hodgkin lymphoma, and kidney cancers. These were selected as auditing was expected to have the greatest impact on reducing unwarranted variation in care. For this reason, there are currently no plans to undertake a national clinical audit for bladder cancer, though bladder cancer outcomes continue to be monitored through existing national cancer datasets.

Improving cancer outcomes, including for bladder cancer, is a priority for the Government. The forthcoming National Cancer Plan will set out further actions to improve earlier diagnosis, expand access to the latest treatments and technologies, and improve survival rates across England.

National cancer registry data shows a small but sustained decline in bladder cancer survival rates over recent years. One-year survival fell from approximately 72% to 69.6%, and five-year survival from 51.5% to 47.2% between 2007 to 2011 and 2016 to 2020.

To improve treatment times, we have invested £70 million of funding into new radiotherapy treatment machines to replace older, less efficient machines. These new machines are currently being rolled out to trusts throughout the country. These newer machines will reduce treatment times, boost productivity, and allow more patients to be seen over the same period.

In addition, non-specific symptom pathways have been introduced to speed up diagnosis for patients whose symptoms may indicate cancer but which do not align clearly with a specific tumour type. This helps ensure that more patients are referred, investigated, and diagnosed earlier, including cases of bladder cancer that present with broader or less specific symptoms.

The NHS Cancer Programme has commissioned 10 national clinical audits covering breast, ovarian, pancreatic, lung, prostate, oesophago-gastric, bowel, non-Hodgkin lymphoma, and kidney cancers. These were selected as auditing was expected to have the greatest impact on reducing unwarranted variation in care. For this reason, there are currently no plans to undertake a national clinical audit for bladder cancer, though bladder cancer outcomes continue to be monitored through existing national cancer datasets.

The Government remains committed to ensuring equitable access to a range of contraceptive methods, including the coil.

Under the GP Contract, contraceptive services are part of the essential services that practices must provide, either directly or by making arrangements for their patients to access them. Integrated care boards (ICBs) may commission GPs to offer long acting reversible contraception, such as the contraceptive coil, as an enhanced service to their local population, in addition to the service provided through the GP Contract. It is for ICBs to decide on commissioning arrangements for their area based on an assessment of local need. Information on levels of staffing, clinic space, equipment and stock availability, and waiting times for coil fittings are not held centrally.

The new HIV Action Plan, published on 1 December 2025, sets out how the Government will enable every level of the healthcare system to work together to engage everyone in prevention, testing and treatment, tackling stigma, and reaching our ambition to end new HIV transmissions by 2030. Services to support people living with HIV are primarily the responsibility of National Health Service integrated care boards, who commission adult HIV care in line with the relevant NHS England service specification. Providers of HIV care are responsible for collaborating with local authority commissioned social care where needed.

The HIV Action Plan also asks local partners across the NHS and local authorities to carry out a HIV needs assessment which will inform the development and publication of local HIV plans across the country during 2026/27. Local areas will monitor uptake and outcomes to identify gaps and improve equity in access to HIV prevention, testing, and treatment. The UK Health Security Agency will continue to support this with robust data monitoring and reporting.

We expect these documents to be published shortly.

The Scientific Advisory Committee on Nutrition (SACN) considered the evidence on the impact of processing on health, including mental health, in 2023 and 2025. The SACN concluded that the observed associations between higher consumption of processed and ultra processed foods and adverse health outcomes are concerning. The SACN noted that studies to date appear to inconsistently account for important factors such as socioeconomic status.

The SACN recommend that on balance, most people are likely to benefit from reducing their consumption of processed foods high in energy, saturated fat, salt, and free sugars, and which are low in fibre. These recommendations align with existing policies for supporting healthier diets and advice to consumers. The SACN will keep the topic of food processing and health under review.

The Department for Environment, Food and Rural Affairs’ 2024 report on Food Insecurity also considered inequalities in access to a healthy sustainable diet. Data from the latest National Diet and Nutrition Survey report shows that participants in higher income households, and households in less deprived areas, were closer to meeting some dietary recommendations. However, where diets failed to meet recommendations, this was consistent across the range of income and deprivation.

The Department of Health and Social Care is working closely with the Department for Environment, Food and Rural Affairs to develop their cross-Government Food Strategy, which aims to improve affordability and access to healthier food, to help both adults and children live longer, healthier lives.

Earlier this year, the Government committed to reviewing the School Food Standards to reflect the most recent Government dietary recommendations. Free school meals will also be extended to all children from households in receipt of Universal Credit from September 2026.

Healthy Start provides funding to pregnant women, babies, and young children under four years old from very low-income households to support a healthier diet. In April 2026, the value of weekly payments will increase by 10%.

The Department is working closely with the Child Poverty Taskforce to develop and deliver an ambitious strategy to reduce child poverty.

Regional cardiovascular disease leads and regional directors hold discussions with local authorities, including in Suffolk, regarding NHS Health Check performance and steps to increase uptake of the programme.

The Suffolk General Practice Federation and Public Health and Communities at Suffolk County Council work collaboratively to increase the uptake of the NHS Health Check programme in a range of ways, including delivering the programme at a variety of community venues, such as community libraries, and raising awareness through printed and social media activities. Further work includes participation in the recent Department-led pilot of heart health checks in workplaces.

Work to improve the impact of the NHS Health Check across England is ongoing and we are carefully considering the recommendations from the National Audit Office’s 2024 report, Progress in preventing cardiovascular disease.

The Government is committed to putting patients first, nationally and in North Herefordshire. That is why, in the Elective Reform Plan, we committed to returning by March 2029 to the National Health Service constitutional standard that 92% of patients wait no longer than 18 weeks from referral to consultant-led treatment. Having delivered 5.2 million extra appointments, we have more than doubled our pledge to deliver an extra two million during our first year in office.

Thanks to our modernisation and record investment, waiting lists have been falling for the first time in over a decade. Since the Government came into office it has decreased by over 230,000, despite over 26.4 million referrals onto the waiting list.

North Herefordshire is predominantly served by the Wye Valley NHS Trust, which has seen recent performance improvement in the trauma and orthopaedic (TO) waiting list. Between July 2024 and September 2025, the proportion of waits within 18 weeks for patients on the TO list increased by 5.7%, to 51.8%. The number waiting more than 52 weeks has also fallen by nearly 40%. Since November, high volume weekend lists for joint replacement procedures have also commenced at the Wye Valley Trust.

Nationally, the number of patients on TO waiting lists waiting within 18 weeks has improved by 3.7% and the number waiting more than 52 weeks has fallen by almost 16,000 over the same period.

We know there is more to do to tackle elective waiting lists including for joint replacement surgery. That is why we have invested £1.65 billion in capital funding in 2025/26 to expand and enhance surgical capacity, which includes funding for surgical hubs, the majority of which offer joint replacement surgeries.

As of December 2025, 123 surgical hubs are operational across England including three in the Herefordshire and Worcestershire Integrated Care System, the most recent being the Wye Valley Elective Surgical Hub which opened in July 2024. These dedicated and protected surgical hubs focus on high volume low complexity surgeries and protect elective care from winter and emergency pressures by using ring-fenced staff and facilities, reducing cancellations and improving efficiency.

Community diagnostic centres (CDCs) are delivering additional, digitally connected diagnostic capacity in England, providing patients with a co-ordinated set of tests in the community in as few visits as possible, to enable fast and accurate diagnoses.

There are no CDCs in the South Holland and the Deepings constituency. However, there are three CDCs located within the NHS Lincolnshire Integrated Care Board, including the Grantham CDC in Grantham. CDCs, even if not local to a constituent, will add capacity to the wider integrated care system and will benefit more than just those patients immediately close to them. Diagnostic services can also be accessed across existing acute capacity, such as at Peterborough City Hospital.

CDCs are now delivering additional tests and checks in 170 sites across the country and have delivered over 9.4 million tests, checks, and scans, including large, standard, and hub and spoke models, since July 2024.

The Elective Reform Plan sets out that the Government will deliver additional CDC capacity in 2025/26 by expanding a number of existing CDCs and building up to five new CDCs. This is funded as part of the £600 million of capital investment for diagnostics in 2025/26, which my Rt. Hon. Friend, the Chancellor of the Exchequer set out in the June 2025 statement.

NHS England is working with local National Health Service systems to identify the most appropriate locations for additional investment, including new CDCs. New CDCs should be positioned in a location which addresses local need and address health inequalities. Details of future sites will be set out in due course.  The locations of both new and expanded CDC schemes will be confirmed in due course.

Over the longer term, as set out in our 10-Year Health Plan, we expect more care to be delivered in community settings, and nearer to patients’ home by default, for example through greater use of point of care tests.

The Government is committed to putting patients first. This means making sure patients are seen on time and have the information they need to have the best possible experience of care.

As set out in the Elective Reform Plan, published January 2025, patients should expect clear communications that meet their needs throughout their time on a waiting list. This includes information about how long they might wait for their appointment and details about how and when to contact their provider. We are currently working with patients and carers to publish minimum standards patients should expect while they wait for planned care. This includes considering patients’ communication needs.

We have also taken steps to deliver important digital interventions to ensure patients can receive clear and timely information whilst waiting for care. Since March 2025, patients at 87% of hospitals can view information about their elective appointments, estimated waiting times, and average waiting times by specialty on the NHS App. By March 2027, we will significantly improve information about waiting times on the NHS App for patients in elective care and will expand proxy access for parents and carers. We will also review the role and functionality of My Planned Care, which currently provides average waiting times and other information for patients waiting for care. High quality non-digital options should always be in place for those that need them.

The Department has held no discussions with National Health Service trusts and clinical directors on surgical trainees’ access to operating theatres.

It is the responsibility of individual employers to ensure their staff have appropriate access to ongoing training and professional development to provide safe and effective care.

While the Department does not hold data specifically on the number of Parkinson’s specialist staff in England, we do hold data on the number of doctors working in the wider specialities of neurology and geriatric medicine. As of August 2025, there were 2,010 full time equivalent (FTE) doctors working in the specialty of neurology and 6,284 in geriatric medicine in National Health Service trusts and other organisations in England. This includes 1,025 FTE consultant neurologists and 1,687 FTE consultant geriatricians.

These figures are based on NHS Digital’s workforce data and reflect staff employed by NHS trusts and other core NHS organisations in England. They do not include doctors working in private practice or outside NHS organisations.

The Department does not hold specific data on the number of specialist Parkinson’s nurses currently working in the NHS in England. These roles are commissioned and managed locally by NHS trusts and integrated care boards as part of neurology and movement disorder services.

NHS England has published a service specification for specialised adult neurology services, which includes Parkinson’s disease as part of its scope. This specification sets out requirements for multidisciplinary care, including access to Parkinson’s disease nurse specialists, consultant neurologists, and allied health professionals.

NHS England is also implementing initiatives such as the Neurology Transformation Programme and the Getting It Right First Time Programme for Neurology, which aim to improve access to specialist care, reduce variation, and develop integrated models of service delivery for conditions including Parkinson’s disease. These programmes align with the National Institute for Care Excellence’s guidance on Parkinson’s disease, reference code NG71, which recommends that people with Parkinson’s have regular access to specialist staff with expertise in the condition.

While the Department does not hold data specifically on the number of Parkinson’s specialist staff in England, we do hold data on the number of doctors working in the wider specialities of neurology and geriatric medicine. As of August 2025, there were 2,010 full time equivalent (FTE) doctors working in the specialty of neurology and 6,284 in geriatric medicine in National Health Service trusts and other organisations in England. This includes 1,025 FTE consultant neurologists and 1,687 FTE consultant geriatricians.

These figures are based on NHS Digital’s workforce data and reflect staff employed by NHS trusts and other core NHS organisations in England. They do not include doctors working in private practice or outside NHS organisations.

The Department does not hold specific data on the number of specialist Parkinson’s nurses currently working in the NHS in England. These roles are commissioned and managed locally by NHS trusts and integrated care boards as part of neurology and movement disorder services.

NHS England has published a service specification for specialised adult neurology services, which includes Parkinson’s disease as part of its scope. This specification sets out requirements for multidisciplinary care, including access to Parkinson’s disease nurse specialists, consultant neurologists, and allied health professionals.

NHS England is also implementing initiatives such as the Neurology Transformation Programme and the Getting It Right First Time Programme for Neurology, which aim to improve access to specialist care, reduce variation, and develop integrated models of service delivery for conditions including Parkinson’s disease. These programmes align with the National Institute for Care Excellence’s guidance on Parkinson’s disease, reference code NG71, which recommends that people with Parkinson’s have regular access to specialist staff with expertise in the condition.

While the Department does not hold data specifically on the number of Parkinson’s specialist staff in England, we do hold data on the number of doctors working in the wider specialities of neurology and geriatric medicine. As of August 2025, there were 2,010 full time equivalent (FTE) doctors working in the specialty of neurology and 6,284 in geriatric medicine in National Health Service trusts and other organisations in England. This includes 1,025 FTE consultant neurologists and 1,687 FTE consultant geriatricians.

These figures are based on NHS Digital’s workforce data and reflect staff employed by NHS trusts and other core NHS organisations in England. They do not include doctors working in private practice or outside NHS organisations.

The Department does not hold specific data on the number of specialist Parkinson’s nurses currently working in the NHS in England. These roles are commissioned and managed locally by NHS trusts and integrated care boards as part of neurology and movement disorder services.

NHS England has published a service specification for specialised adult neurology services, which includes Parkinson’s disease as part of its scope. This specification sets out requirements for multidisciplinary care, including access to Parkinson’s disease nurse specialists, consultant neurologists, and allied health professionals.

NHS England is also implementing initiatives such as the Neurology Transformation Programme and the Getting It Right First Time Programme for Neurology, which aim to improve access to specialist care, reduce variation, and develop integrated models of service delivery for conditions including Parkinson’s disease. These programmes align with the National Institute for Care Excellence’s guidance on Parkinson’s disease, reference code NG71, which recommends that people with Parkinson’s have regular access to specialist staff with expertise in the condition.

We know that we need to do more to improve health outcomes for men across the country, including men in Surrey Heath. On 19 November, to coincide with International Men’s Health Day, we published the Men’s Health Strategy which aims to improve the health of all men and boys in England. The strategy includes tangible actions to improve access to healthcare, provide the right support to enable men to make healthier choices, develop healthy living and working conditions, foster strong social, community and family networks, and address societal norms. It also considers how to prevent and tackle the biggest health problems affecting men of all ages, which include mental health and suicide prevention, respiratory illness, prostate cancer, and heart disease.

This strategy is a crucial first step, laying the foundation from which we can learn, iterate and grow to create a society where all men and boys are supported to live longer, healthier and happier lives. As a first step, we will work with the Men’s Health Academic Network and voluntary, community and social enterprise sector to develop and publish a one-year-on report, highlighting the improvements made and where future efforts will need to be targeted.

No specific assessment has been made of the potential impact of delayed access to specialist heart valve disease (HVD) treatment on avoidable unscheduled hospitalisations, deaths on waiting lists, or other patient outcomes.

Cutting waiting times, including for cardiology services, is a key priority for the Government. The cardiology waiting list decreased from 412,164 in September 2024 to 393,400 in September 2025, although this data includes estimates for missing data.

Cardiology is a priority specialty for significant transformation, as outlined in the Elective Reform Plan. The ambition is, where possible and clinically appropriate, to increase specialist care closer to home, and outside of hospitals so that hospital capacity is freed up, enabling patients' timely access to care, as well as improving outcomes.

NHS England has committed to optimising pathways of care for patients with HVD, including earlier detection and improved treatment pathways. To achieve this, the NHS England Cardiac Programme has established an expert advisory group and carried out work including, in 2024/25, providing targeted funding for pathway improvement projects. These included projects that focussed on improving referral processes and local diagnostic pathway provision, as well as fast-tracking patients on valve disease pathways.

To accelerate progress towards the Government’s ambition to reduce premature deaths from heart disease and stroke by 25% within a decade, we will publish a new cardiovascular disease modern service framework in 2026.

The Government understands the importance and significance of National Grief Awareness Week. Grief is something we will all encounter during our lives, and it’s important that grieving families and friends who have lost loved ones have access to the support they need, when they need it.

As part of National Grief Awareness Week 2025, the Parliamentary Under-Secretary of State for Patient Safety, Women’s Health and Mental Health met with the UK Commission on Bereavement. This was highlighted on social media, with further information available at the following link:

https://www.linkedin.com/posts/baroness-gillian-merron-a5130330_yesterday-during-national-grief-awareness-activity-7402274226902040576-PSWO

Furthermore, the Department chairs the cross-Government Bereavement Working Group, with representatives from over 10 departments, to consider options to improve bereavement support and services.

The Government’s advice on a healthy, balanced diet is encapsulated in the United Kingdom’s national food model, the Eatwell Guide. The Eatwell Guide applies to most people from the age of two years old, and is available at the following link:

https://www.gov.uk/government/publications/the-eatwell-guide#

The Eatwell Guide’s principles are communicated through a variety of channels, including the NHS.UK website and Department social marketing campaigns, which encompass Better Health, Better Health Families, and Best Start in Life. This includes a series of websites and digital tools that support families with young children to eat better, providing guidance on healthy eating, such as the Food Scanner app and email programmes.

Education around healthy eating is also covered through a number of school curriculum subjects.

The Eatwell Guide also underpins Government catering guidance and standards. Earlier this year, the Government committed to reviewing the School Food Standards to reflect the most recent Government dietary recommendations. These standards are available at the following link:

https://www.gov.uk/government/publications/school-food-standards-resources-for-schools/school-food-standards-practical-guide

As set out in our 10-Year Health Plan, the Government has committed to actions to encourage a food environment that supports everyone, including young people, to make healthier choices, including:

• implementing restrictions on the advertising of less healthy food or drink products on television before 9:00pm and all paid-for advertising online;
• consulting on our plans to ban the sale of high-caffeine energy drinks to children under 16 years old; and
• using our Revised National Planning Policy Framework to give local authorities stronger powers to block new fast-food outlets near schools.

Further information on the 10-Year Health Plan is available at the following link:

https://www.gov.uk/government/publications/10-year-health-plan-for-england-fit-for-the-future

There are a range of actions that have already been taken, including the Soft Drinks Industry Levy, location promotions restrictions, and calorie labelling. Prior to the General Election in July 2024, the Department also legislated to introduce restrictions on the volume price promotions retailers can offer on ‘less healthy’ food and drink in stores and their equivalent places online. These measures came into force in England on 1 October 2025.

In July this year, we published the final delivery plan (FDP) for myalgic encephalomyelitis, also known as chronic fatigue syndrome (ME/CFS), which focuses on boosting research, improving attitudes and education, and bettering the lives of people with this debilitating disease.

To support healthcare professionals in the diagnosis and management of ME/CFS, as set out in the FDP, the Department has worked with NHS England to develop an e-learning programme on ME/CFS for healthcare professionals, with the aim of supporting staff to be able to provide better care and improve patient outcomes. All three sessions of the e-learning programme, with sessions one and two having universal access, whilst the third session is only available to healthcare professionals, are now available at the following link:

https://learninghub.nhs.uk/catalogue/mecfselearning?nodeId=7288

To support healthcare professionals in the diagnosis and management of ME/CFS, the National Institute for Health and Care Excellence published guidance, which can be found at the following link:

https://www.nice.org.uk/guidance/ng206

It recommends that people with ME/CFS should be referred for a dietetic assessment by a dietician with a special interest in ME/CFS if they are losing weight and are at risk of malnutrition. The guidance also states that clinicians should recognise that symptoms of severe and very severe ME/CFS may mean that people are unable to eat and digest food easily, and may need support with hydration and nutrition. It suggests that managing this risk could include oral nutrition and enteral feeding.

The FDP includes an action for the Department and NHS England to explore whether a specialised service should be prescribed by my Rt Hon. Friend, the Secretary of State for Health and Social Care, for very severe ME/CFS. Officials from the Department have commenced discussions with NHS England on how best to take forward this action.

The policy for the respiratory syncytial virus (RSV) programme is based on the advice of the Joint Committee on Vaccination and Immunisation (JCVI), an independent expert advisory committee. The JCVI considered RSV modelling that included different levels of uptake for maternal or infant immunisation. The JCVI advised that either antenatal maternal vaccination or infant monoclonal antibody immunisation strategies could be suitable for a universal United Kingdom programme and did not have a preference. Maternal vaccination became the UK programme from September 2024 following a competitive tender.

The JCVI had noted that protection of preterm infants would need to be looked at if the UK adopted a maternal vaccination programme. At the October 2024 meeting the JCVI advised that a programme to extend a potential offer of nirsevimab, a monoclonal antibody, to very and extremely premature infants could be cost effective.

Based on JCVI’s advice, the RSV selective immunisation programme for high-risk infants switched in September 2025 from using palivizumab to using nirsevimab, and was extended to include premature babies born at less than 32 weeks gestation.

In Fit for the Future: 10-Year Health Plan for England, the Government has committed to exploring whether to raise the upper alcohol limit for drinks labelled as alcohol-free to 0.5% alcohol by volume (ABV) from 0.05% ABV, as set out in the current labelling guidance for no and low (NoLo) alcohol drink alternatives.

Department officials are progressing work to take forward this commitment, and we will update stakeholders in due course. The consultation referred to was undertaken by the previous administration. A decision on publishing a response will be made as part of determining the delivery timescales of the NoLo commitments in the 10-Year Health Plan.

The Government is developing a Palliative Care and End of Life Care Modern Service Framework (MSF) for England. I refer the hon. Member to the Written Ministerial Statement HCWS1087 I gave to the House on 24 November 2025.

Through our MSF, we will closely monitor the shift towards strategic commissioning of palliative care and end of life care services to ensure that services reduce variation in access to, and quality of, palliative and end of life care services at local and regional levels.

This is further made clear in the recently published Strategic Commissioning Framework and Medium Term Planning Guidance, which make clear the expectations that integrated care boards should understand current and projected total service utilisation and costs for those at the end of life, creating an overall plan to more effectively meet these needs through neighbourhood health.

The Government is developing a Palliative Care and End of Life Care Modern Service Framework (MSF) for England. I refer the hon. Member to the Written Ministerial Statement HCWS1087 I gave to the House on 24 November 2025.

Through our MSF, we will closely monitor the shift towards strategic commissioning of palliative care and end of life care services to ensure that services reduce variation in access to, and quality of, palliative and end of life care services at local and regional levels.

This is further made clear in the recently published Strategic Commissioning Framework and Medium Term Planning Guidance, which make clear the expectations that integrated care boards should understand current and projected total service utilisation and costs for those at the end of life, creating an overall plan to more effectively meet these needs through neighbourhood health.

The Government is taking steps to prevent, diagnose, and treat cancers more quickly, including skin cancers. The forthcoming National Cancer Plan will cover the entirety of the cancer pathway from referral and diagnosis to treatment and ongoing care. It will set out how we will improve outcomes for cancer patients, including by speeding up diagnosis and treatment, ensuring patients have access to the latest treatments and technology, and ultimately driving up this country’s cancer survival rates. We will publish the National Cancer Plan in the new year to reduce the number of lives lost to cancer over the next 10 years.

We received over 11,000 responses to our call for evidence from individuals, professionals, and organisations, and we are reviewing the submissions from skin cancer partners. While no formal assessment has been made of the availability and levels of use of tan-enhancing products containing Melanotan II, respondents shared concerns about tanning products and their potential links to cancer, particularly melanoma. Our expansive engagement will allow the National Cancer Plan to have patients at its heart.

The Medicines and Healthcare products Regulatory Agency (MHRA) is responsible for the regulation of medicinal products and medical devices in the United Kingdom. Although tanning is not considered to be a medical purpose, injectable products containing Melanotan I or Melanotan II have been determined as medicinal products due to their similarity to the authorised medicine Scenesse.

In relation to nasal sprays containing Melanotan I or Melanotan II, there are no equivalent authorised medicines and in the absence of medicinal claims, they are not regarded as medicinal products.

Medicinal products must hold a relevant Marketing Authorisation to be legally sold and supplied in the UK. This also guarantees that the medicines have been tested for conformity with strict standards of quality, safety, and efficacy.

The MHRA takes action when a medicinal product without appropriate authorisations is identified.

In England, the National Institute for Health and Care Excellence (NICE) makes recommendations for the National Health Service on whether new licensed medicines should be routinely funded by the NHS based on an assessment of clinical and cost effectiveness. The NHS is legally required to fund NICE recommended medicines, normally within three months of final guidance, and cancer medicines are eligible for funding from the point of a positive draft NICE recommendation. NICE aims wherever possible to issue guidance on new medicines close to the time of licensing to ensure that patients are able to benefit from rapid access to clinically and cost effective new medicines.

The Life Sciences Sector Plan sets out the measures we are taking that will mean that patients are able to access medicines three to six months faster, including improved alignment between the Medicines and Healthcare products Regulatory Agency’s decisions and NICE guidance publication.

In England in 2024/25, 93% of NICE recommendations for cancer treatments were positive. Positive includes recommended, optimised, recommended in the cancer drugs fund (CDF), and optimised in the CDF.

Health is a devolved matter and as such it would not be appropriate for me to comment on access to medicines within the devolved administrations.

The Department does not hold this data, although published data from NHS England is available from 2022 for the cancer waiting time standards, at the following link:

https://www.england.nhs.uk/statistics/statistical-work-areas/cancer-waiting-times/

Cancer waiting times data can be broken down by integrated care board or National Health Service trust, however, this data is not available by constituency. The local NHS trusts for the South Holland and the Deepings constituency are North West Anglia, The Queen Elizabeth Hospital King's Lynn, and United Lincolnshire Teaching Hospitals.

In the United Kingdom, national screening programmes are introduced based on the recommendations of the UK National Screening Committee (UK NSC), an independent scientific advisory committee which advises ministers and the National Health Service in all four countries on all aspects of population and targeted screening, and which supports implementation.

The UK NSC last reviewed screening for sudden cardiac death (SCD) in people under the age of 39 years old in 2019 and concluded that population screening should not be offered. Further information is available at the following link:

https://view-health-screening-recommendations.service.gov.uk/sudden-cardiac-death/

The UK NSC is currently examining the evidence for SCD screening and will open a public consultation to seek comments from members of the public and stakeholders on this in due course.

In the United Kingdom, new screening programmes and modifications to existing screening programmes are recommended by the UK National Screening Committee (UK NSC), an independent scientific advisory committee.

The UK NSC received a submission via its 2024 open call process to consider screening for autoimmune type 1 diabetes through blood testing. Once the National Institute for Health and Care Excellence has published its recommendation on the drug teplizumab, the UK NSC will look again at this open call submission and consider whether a fresh review of the evidence for type 1 diabetes screening should be undertaken.

The Government is committed to improving care for people living with Crohn’s disease and ulcerative colitis, including those in the Ashfield constituency. NHS England supports local integrated care boards to deliver high-quality, timely services through initiatives such as the Getting It Right First Time (GIRFT) programme. GIRFT promotes earlier diagnosis, proactive management of flare-ups, and consistent adoption of best practice. Its gastroenterology report and updated inflammatory bowel disease (IBD) pathway recommend measures such as rapid access to specialist review within four weeks, personalised care plans, and expanded endoscopy capacity. These changes aim to cut emergency admissions, improve quality of life, and ensure equitable access to specialist nurses and multidisciplinary support across the country. The GIRFT programme has recently published a new handbook pulling together examples of innovative practice, proven solutions, and practical actions to help optimise the care of National Health Service patients with IBD. The GIRFT IBD pathway and associated handbook include specific guidance for paediatric care and the transition to adult services, recognising the unique needs of children and young people with Crohn’s disease and ulcerative colitis. The handbook is available at the following link:

https://gettingitrightfirsttime.co.uk/practical-advice-and-key-actions-in-new-girft-handbook-for-optimising-the-care-of-patients-with-ibd/

The 10-Year Health Plan will further improve care and support for people with IBD by expanding community diagnostic centres, reducing waiting times for endoscopy and imaging, and integrating digital tools to streamline referrals and follow-up care. It prioritises early diagnosis, personalised treatment plans, and better coordination between primary and specialist services. Investment in multidisciplinary teams will ensure patients receive timely, high-quality care. In addition, initiatives such as Diagnosis Connect will, from 2026, provide newly diagnosed patients with tailored information and support, empowering them to manage their condition confidently.

The NHS website provides comprehensive, accessible information on Crohn’s disease and ulcerative colitis, helping to raise public awareness and understanding of these conditions. The site explains what Crohn’s and colitis are, outlines common symptoms, and gives clear guidance on when to seek medical advice. It also details how these conditions are diagnosed and managed, including available treatments and support services.

To raise awareness of IBD among general practitioners and other primary care staff, the Royal College of General Practitioners has produced an Inflammatory Bowel Disease Toolkit. The toolkit outlines when to suspect IBD, the appropriate investigative tests and diagnostic tools for IBD, how to manage a flare-up of symptoms, and how to support patients with IBD.

The Government is committed to improving care for people living with Crohn’s disease and ulcerative colitis, including those in the Ashfield constituency. NHS England supports local integrated care boards to deliver high-quality, timely services through initiatives such as the Getting It Right First Time (GIRFT) programme. GIRFT promotes earlier diagnosis, proactive management of flare-ups, and consistent adoption of best practice. Its gastroenterology report and updated inflammatory bowel disease (IBD) pathway recommend measures such as rapid access to specialist review within four weeks, personalised care plans, and expanded endoscopy capacity. These changes aim to cut emergency admissions, improve quality of life, and ensure equitable access to specialist nurses and multidisciplinary support across the country. The GIRFT programme has recently published a new handbook pulling together examples of innovative practice, proven solutions, and practical actions to help optimise the care of National Health Service patients with IBD. The GIRFT IBD pathway and associated handbook include specific guidance for paediatric care and the transition to adult services, recognising the unique needs of children and young people with Crohn’s disease and ulcerative colitis. The handbook is available at the following link:

https://gettingitrightfirsttime.co.uk/practical-advice-and-key-actions-in-new-girft-handbook-for-optimising-the-care-of-patients-with-ibd/

The 10-Year Health Plan will further improve care and support for people with IBD by expanding community diagnostic centres, reducing waiting times for endoscopy and imaging, and integrating digital tools to streamline referrals and follow-up care. It prioritises early diagnosis, personalised treatment plans, and better coordination between primary and specialist services. Investment in multidisciplinary teams will ensure patients receive timely, high-quality care. In addition, initiatives such as Diagnosis Connect will, from 2026, provide newly diagnosed patients with tailored information and support, empowering them to manage their condition confidently.

The NHS website provides comprehensive, accessible information on Crohn’s disease and ulcerative colitis, helping to raise public awareness and understanding of these conditions. The site explains what Crohn’s and colitis are, outlines common symptoms, and gives clear guidance on when to seek medical advice. It also details how these conditions are diagnosed and managed, including available treatments and support services.

To raise awareness of IBD among general practitioners and other primary care staff, the Royal College of General Practitioners has produced an Inflammatory Bowel Disease Toolkit. The toolkit outlines when to suspect IBD, the appropriate investigative tests and diagnostic tools for IBD, how to manage a flare-up of symptoms, and how to support patients with IBD.

The Government is committed to improving care for people living with Crohn’s disease and ulcerative colitis, including those in the Ashfield constituency. NHS England supports local integrated care boards to deliver high-quality, timely services through initiatives such as the Getting It Right First Time (GIRFT) programme. GIRFT promotes earlier diagnosis, proactive management of flare-ups, and consistent adoption of best practice. Its gastroenterology report and updated inflammatory bowel disease (IBD) pathway recommend measures such as rapid access to specialist review within four weeks, personalised care plans, and expanded endoscopy capacity. These changes aim to cut emergency admissions, improve quality of life, and ensure equitable access to specialist nurses and multidisciplinary support across the country. The GIRFT programme has recently published a new handbook pulling together examples of innovative practice, proven solutions, and practical actions to help optimise the care of National Health Service patients with IBD. The GIRFT IBD pathway and associated handbook include specific guidance for paediatric care and the transition to adult services, recognising the unique needs of children and young people with Crohn’s disease and ulcerative colitis. The handbook is available at the following link:

https://gettingitrightfirsttime.co.uk/practical-advice-and-key-actions-in-new-girft-handbook-for-optimising-the-care-of-patients-with-ibd/

The 10-Year Health Plan will further improve care and support for people with IBD by expanding community diagnostic centres, reducing waiting times for endoscopy and imaging, and integrating digital tools to streamline referrals and follow-up care. It prioritises early diagnosis, personalised treatment plans, and better coordination between primary and specialist services. Investment in multidisciplinary teams will ensure patients receive timely, high-quality care. In addition, initiatives such as Diagnosis Connect will, from 2026, provide newly diagnosed patients with tailored information and support, empowering them to manage their condition confidently.

The NHS website provides comprehensive, accessible information on Crohn’s disease and ulcerative colitis, helping to raise public awareness and understanding of these conditions. The site explains what Crohn’s and colitis are, outlines common symptoms, and gives clear guidance on when to seek medical advice. It also details how these conditions are diagnosed and managed, including available treatments and support services.

To raise awareness of IBD among general practitioners and other primary care staff, the Royal College of General Practitioners has produced an Inflammatory Bowel Disease Toolkit. The toolkit outlines when to suspect IBD, the appropriate investigative tests and diagnostic tools for IBD, how to manage a flare-up of symptoms, and how to support patients with IBD.

The Government is committed to improving care for people living with Crohn’s disease and ulcerative colitis, including those in the Ashfield constituency. NHS England supports local integrated care boards to deliver high-quality, timely services through initiatives such as the Getting It Right First Time (GIRFT) programme. GIRFT promotes earlier diagnosis, proactive management of flare-ups, and consistent adoption of best practice. Its gastroenterology report and updated inflammatory bowel disease (IBD) pathway recommend measures such as rapid access to specialist review within four weeks, personalised care plans, and expanded endoscopy capacity. These changes aim to cut emergency admissions, improve quality of life, and ensure equitable access to specialist nurses and multidisciplinary support across the country. The GIRFT programme has recently published a new handbook pulling together examples of innovative practice, proven solutions, and practical actions to help optimise the care of National Health Service patients with IBD. The GIRFT IBD pathway and associated handbook include specific guidance for paediatric care and the transition to adult services, recognising the unique needs of children and young people with Crohn’s disease and ulcerative colitis. The handbook is available at the following link:

https://gettingitrightfirsttime.co.uk/practical-advice-and-key-actions-in-new-girft-handbook-for-optimising-the-care-of-patients-with-ibd/

The 10-Year Health Plan will further improve care and support for people with IBD by expanding community diagnostic centres, reducing waiting times for endoscopy and imaging, and integrating digital tools to streamline referrals and follow-up care. It prioritises early diagnosis, personalised treatment plans, and better coordination between primary and specialist services. Investment in multidisciplinary teams will ensure patients receive timely, high-quality care. In addition, initiatives such as Diagnosis Connect will, from 2026, provide newly diagnosed patients with tailored information and support, empowering them to manage their condition confidently.

The NHS website provides comprehensive, accessible information on Crohn’s disease and ulcerative colitis, helping to raise public awareness and understanding of these conditions. The site explains what Crohn’s and colitis are, outlines common symptoms, and gives clear guidance on when to seek medical advice. It also details how these conditions are diagnosed and managed, including available treatments and support services.

To raise awareness of IBD among general practitioners and other primary care staff, the Royal College of General Practitioners has produced an Inflammatory Bowel Disease Toolkit. The toolkit outlines when to suspect IBD, the appropriate investigative tests and diagnostic tools for IBD, how to manage a flare-up of symptoms, and how to support patients with IBD.

Working under the UK Rare Diseases Framework the Government is committed to improving the lives of those living with rare diseases. NHS England and the Department are strongly supportive of clinical leadership and recognise that national clinical directors play an important role in policy development and implementation. There are over 7,000 types of rare disease which span the range of clinical specialities. As such, NHS England and the Department expect to continue to draw upon the range of clinical expertise that their national clinical directors hold to inform our work in this area, as well as that of expert clinicians delivering services for rare diseases, such as those commissioned by specialised commissioning. In addition, there is a National Medical Director for Specialised Services who provides national leadership and advice for the healthcare of rare disease and oversight for the portfolio of rare diseases which NHS England commissions services for.

To coincide with World Diabetes Day on 14 November 2025, NHS England, in partnership with other key national stakeholders, launched a national awareness campaign to promote health care professionals in their identification and diagnosis of type 1 diabetes and reduce the risk of misdiagnosis.

This included a call to action to healthcare professionals, signposting to information, and action to take if a person is displaying any of the symptoms of type 1 diabetes, as well as supportive resources.

We are not aware of clear evidence to show that a ban on filters would lead to reductions in smoking rates. We are confident the best way to protect people’s health is to reduce the prevalence of smoking. That is why we are taking decisive action through the Tobacco and Vapes Bill to create a smoke-free generation alongside continuing with evidence-based approaches to supporting smokers to quit. We therefore have no current plans to ban cigarette filters.

A national Task and Finish Group has been established by NHS England which brings together key experts from across the health system, including academia/research and leading national clinicians, to jointly assess the opportunities and challenges that are associated with a national screening programme for diabetes and to inform the national direction of travel with regard to the development of national policy in this area.

To reduce variation and health inequalities, data on the uptake of continuous glucose monitors (CGM) for diabetics is collected as part of the National Diabetes Audit (NDA).

NHS England plans to routinely publish this data in the NDA Core Quarterly dashboard in 2025/26, which will provide the data insights integrated care boards require to deliver CGM to their populations.

To enable faster diagnosis and earlier access to treatment for chronic obstructive pulmonary disease (COPD), access to spirometry tests in community diagnostic centres (CDCs) is growing and will continue to do so as more sites come online. The first five months of 2025/26 saw an increase in CDC spirometry testing of approximately 2,000 tests per month more than in the previous year.

As of November 2025, CDCs are now delivering additional tests and checks in 170 sites across the country. 101 CDCs across the country now offer out of hours services, 12 hours a day, seven days a week, meaning patients can access vital diagnostic tests around their busy working lives.

Diagnosis times for COPD from spirometry tests are not routinely collected or available in a centralised dataset.

To enable faster diagnosis and earlier access to treatment for chronic obstructive pulmonary disease (COPD), access to spirometry tests in community diagnostic centres (CDCs) is growing and will continue to do so as more sites come online. The first five months of 2025/26 saw an increase in CDC spirometry testing of approximately 2,000 tests per month more than in the previous year.

As of November 2025, CDCs are now delivering additional tests and checks in 170 sites across the country. 101 CDCs across the country now offer out of hours services, 12 hours a day, seven days a week, meaning patients can access vital diagnostic tests around their busy working lives.

Diagnosis times for COPD from spirometry tests are not routinely collected or available in a centralised dataset.